GP
CLVS

GLG Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

GLG Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,000
Closed -$180K – 480
2016
Q3 		$180K Buy
+5,000
New +$107K 0.01% 421

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

GLG Partners's CLVS Position: Q4 2017 in Review

GLG Partners reduced its Clovis Oncology, Inc. (CLVS) stake by 16% in Q4 2017, selling an estimated $24.3K and leaving 1,886 shares worth $128K. The position accounts for 0.01% of the portfolio, ranked #403.

GLG Partners first reported a position in CLVS in Q3 2014 and has held it in 6 quarters since. The position peaked at $3.53M in Q3 2015. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

  • GLG Partners held 1,886 shares of Clovis Oncology, Inc. worth $128K as of Q4 2017.
  • GLG Partners sold 347 Clovis Oncology, Inc. shares in Q4 2017, an estimated $24.3K.
  • Clovis Oncology, Inc. made up 0.01% of GLG Partners's portfolio in Q4 2017, its #403 holding.
  • GLG Partners first reported a position in Clovis Oncology, Inc. in Q3 2014 and has held it in 6 quarters since.
  • GLG Partners's Clovis Oncology, Inc. position peaked at $3.53M in Q3 2015.
  • 247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.